
Eli Lilly’s Profits Skyrocket on Success of Mounjaro and Zepbound
Pharmaceutical giant Eli Lilly delivered a stellar second-quarter performance, beating analysts’ expectations and raising its full-year outlook by a whopping $3 billion. The company’s flagship diabetes drug, Mounjaro, and its weight-loss counterpart, Zepbound, were the main drivers of the stellar growth. Mounjaro and Zepbound, both incretin drugs, have seen unprecedented demand, leading to supply constraints…